Mechanisms of Melatonin-Induced Protection in the Brain of Late Gestation Fetal Sheep in Response to Hypoxia

Tamara Yawno  Margie Castillo-Melendez  Graham Jenkin  Euan M. Wallace  David W. Walker  Suzanne L. Miller

The Ritchie Centre, Monash Institute of Medical Research, and Department of Obstetrics and Gynaecology, Monash University, Clayton, Vic., Australia

Key Words
Melatonin · Neuroprotection · Fetal brain · Sheep · Umbilical cord occlusion

Abstract
Melatonin has diverse physiological actions in addition to its well-recognized maintenance roles in circadian and seasonal timing. In particular, melatonin may have a direct protective action on the developing fetal brain. We examined the cellular processes by which melatonin provides protection following an acute late gestation hypoxic insult. 15 fetal sheep at 126 days’ gestation were instrumented with a brachial artery catheter and a silastic cuff around the umbilical cord. At ~130 days’ gestation, the cuff was inflated for 10 min in 10 fetuses, causing complete umbilical cord occlusion (UCO). 5 UCO fetuses received intravenous melatonin maternally for 2 h, before and after UCO (UCO + melatonin). The remaining 5 fetuses had no UCO performed (sham-operated controls). At 48 h after UCO, the fetal brain was collected from each animal. Compared to controls, UCO caused significant hypoxia, hypercapnia and acidosis in UCO and UCO + melanotin fetuses. In the UCO-alone animals there were significant increases in pyknotic cell death, in the hippocampus (>7-fold) and the cerebellum (3-fold). Maternal melatonin administration ameliorated cellular pyknosis in UCO fetuses. UCO was also associated with astrogliosis, increased albumin uptake, activated microglia and lipid peroxidation. Melatonin prevented these effects. There were no significant differences in the number of brain macrophages or microglia between any of the groups. Following acute severe hypoxia in the late gestation fetus, melatonin reduces neuronal lipid peroxidation and prevents loss of blood-brain barrier integrity and astrogliosis. These are likely key mechanisms underlying the neuroprotective actions of melatonin in the fetal brain.

Introduction
Perinatal hypoxia-ischemia is thought to be one of the principal causes of neonatal encephalopathy [1] and subsequent neurodevelopmental impairment and cerebral palsy [2]. Brief but severe fetal hypoxia-ischemia can be induced experimentally in pregnant animals by umbilical cord occlusion (UCO), resulting in perinatal brain injury similar to that in human babies, and therefore assisting with our knowledge of the mechanisms and susceptibility of the brain to injury [3–5]. While the pattern of brain
injury depends on a number of factors such as gestational age [6, 7], and severity and length of the asphyxia [4, 6–9], it is generally agreed that white matter brain injury predominates in the preterm brain, reflecting the sensitivity of oligodendrocyte precursors to injury [10–12], whereas region-specific neuronal loss in the hippocampus, basal ganglia and cerebellum is more common in late gestation [4, 6, 7, 12, 13].

The sequence of events following a severe hypoxic episode includes not only a primary wave of cell death, which is principally necrotic, but also a secondary phase of delayed and sustained energy failure during which many more cells either die or are committed to a programmed (apoptotic) cell death pathway [12, 14, 15]. Importantly, oxidative stress has a role in both the early and secondary phases of cerebral tissue damage, as shown by the biphasic increase in hydroxyl radical formation that occurs in grey and white matter of the fetal sheep brain following acute in utero hypoxia in late gestation [16]. The fetal brain has a high lipid content, making it vulnerable to the effects of both oxygen and nitrogen free radicals on protein and lipid structure and function and against which endogenous antioxidant enzymes have limited capacity to protect [17, 18].

Antioxidant therapy may prevent or ameliorate brain tissue damage following hypoxia [19–22]. In support of this proposal, we have shown that the administration of melatonin prior to an acute hypoxic event in the late gestation sheep fetus abolishes both the primary and secondary increases in brain hydroxyl radical formation and reduces cerebral lipid peroxidation [23]. Others have shown that melatonin reduces oxidative stress and cell damage in the immature fetal sheep brain in response to severe hypoxia [20], and, in fetal and neonatal rats, melatonin improves indices of brain mitochondrial injury and protects against hippocampal cell loss following cerebral ischemia and reperfusion [24–26]. Melatonin also demonstrates anti-inflammatory properties, stimulates placental expression of antioxidant enzymes, increases placental efficiency and enhances umbilical flow in compromised pregnancies [27–29]; all actions which are likely to protect the developing fetus.

This study was undertaken to investigate whether melatonin reduces the cellular responses to injury within the brain following a brief asphyxial episode. We hypothesized that acute fetal hypoxia, as could occur in perinatal hypoxia-ischemia, induces brain oxidative stress and inflammation in the late gestation brain, and melatonin mediates oxidative and inflammatory responses to reduce brain damage.

### Experimental Procedures

#### Animals

Fifteen pregnant Merino-Border Leicester ewes of known gestational age, carrying singleton fetuses, were used for this study. The ewes were kept in individual cages with free access to food and water under a 12 h light/dark cycle (lights on 07:00 h, off 19:00 h). The use of these animals as well as the procedures performed was in accordance with the Code of Practice for the Care and Use of Animals for Scientific Purposes of the National Health and Medical Research Council of Australia, and had received prior approval from the School of Biomedical Sciences, Monash University Standing Committee on Ethics and Animal Experimentation.

#### Surgical Preparation

At 126 ± 2 days’ gestation (term is about 147 days) surgery was performed under 2–3% halothane (Merial, Parramatta, N.S.W., Australia) general anesthesia for implantation of fetal catheters and an umbilical cuff. Using a midline abdominal incision, the pregnant uterus was identified, opened and the fetal head and right forelimb exteriorized. A sterile polyvinyl catheter (1.5 mm outer diameter, 0.8 mm inner diameter) was inserted into the fetal right brachial artery to allow fetal arterial blood sampling. An inflatable silastic cuff (16HD; In Vivo Medical, Ukiah, Calif., USA) was placed around the umbilical cord which, when inflated with 2–3 ml of sterilized water, would cause complete cessation of umbilical blood flow. Once instrumented, the fetus was returned to the uterus and the uterus was repaired in two layers. The catheters were exteriorized from the maternal abdomen through a small flank incision. A maternal jugular vein catheter (2.7 mm outer diameter, 1.5 mm inner diameter) was also implanted for melatonin infusion. The ewe and fetus were allowed 3–4 days of recovery before beginning the experiment.

#### Experimental Design

At approximately 130 days’ gestation, animals were randomly assigned to either a sham UCO (control) group in which the ewe received a vehicle infusion (n = 5), UCO + vehicle group (UCO: n = 5), or UCO + melatonin group (n = 5). Melatonin (Sigma-Aldrich, Castle Hill, N.S.W., Australia) was dissolved in absolute ethanol and diluted to 0.08 mg/ml using sterile physiological saline, so that the concentration of ethanol in the final solution was 1%. At 12:00 h, a 1-mg melatonin bolus in 5 ml saline was administered to the ewe’s jugular vein, followed by infusion of 10 ml of 0.2 mg/ml melatonin over 2 h. Control animals received an equal volume of the vehicle. One hour after the start of melatonin infusion, a 10-min complete UCO was performed by inflating the cuff with sterile water. For the control group, the cuff was not inflated. Fetal (2-ml) blood samples were taken before, during and after the start of the occlusion, with 0.5 ml of fetal blood used immediately for measurement of pH, oxygen saturation (O2 %), pO2 and pCO2, using an ABL 510 blood gas analyzer (Radiometer, Copenhagen, Denmark). The ewe and fetus were killed 48 h after the start of UCO or control by an intravenous injection of pentobarbitone sodium (Letharb; Virbac Pty Ltd, Peakhurst, N.S.W., Australia) administered to the ewe. The fetal brain was immediately perfused via the carotid artery with 1 liter of 4% paraformaldehyde (ProSci Tech, Thuringowa, Qld., Australia) in 0.1 M phosphate buffer (pH 7.4). The brain was then removed from the skull and post-fixed in 4% paraformaldehyde for 24 h, prior to embedding in paraffin.
Subsequently, 10μm coronal sections of the fetal brain were cut and stained with hematoxylin and eosin for identification of cellular pyknosis and adjacent sections were used for immunohistochemistry.

**Immunohistochemistry**

All sections were placed on SuperFrost Plus glass slides and dewaxed in xylene and rehydrated through a series of ethanol dilutions. Sections were coverslipped using aqueous mounting medium (Dako Australia, Campbellfield, Vic., Australia), after drying at room temperature, for fluorescent sections or using DEPX (Merck, Kilsyth, Vic., Australia) for non-fluorescent sections. For each immunohistochemical protocol, sections containing a specific brain region from all treatment groups were included in a single run to eliminate inter-run variation.

For single-label immunohistochemistry, sections were heated with citric acid buffer for 3 × 5 min followed by incubation in 3% hydrogen peroxide in methanol to remove endogenous peroxidase activity. Sections were then incubated in blocking solution (phosphate-buffered saline, PBS; 0.1 mol/l, pH 7.4), 0.25% Triton X-100 and 5% normal goat serum for 1 h at room temperature to block non-specific binding, followed by incubation with primary antibody in either anti-glial fibrillary acidic protein (GFAP) antibody to identify mature astrocytes or mature neurons, respectively. Sections were subsequently incubated in a 1:400 dilution of secondary antibody (Vector Laboratories) to detect anti-rabbit or anti-mouse IgG antibody; Vector Laboratories, Burlingame, Calif., USA) for 1 h at room temperature, for fluorescent sections or using DEPX waxes. These sections were treated with a serum-free protein blocker (Dako) to prevent background staining, and incubated with either monoclonal anti-GFAP (1:400), or anti-NeuN (1:200; Chemicon Int., Temecula, Calif., USA) to identify mature astrocytes or mature neurons, respectively. Sections were subsequently exposed to the appropriate rabbit polyclonal antibody to identify either 4-HNE (1:1,000), or activated caspase-3 (1:1,000). Immunoreactivity was visualized with Alexa Fluor 594 goat anti-mouse (1:1,000; Molecular Probes, Eugene, Oreg., USA) and Alexa Fluor 488 goat anti-rabbit (1:1,000; Molecular Probes), and viewed with a fluorescent microscope (Olympus) at 400× magnification.

**Statistical Analysis**

Data are presented as mean ± SEM. Physiological data over time were analyzed using a two-way repeated-measures analysis of variance with Tukey post hoc analysis. Cell counts were analyzed by one-way ANOVA and Bonferroni adjustment. Statistical significance was set at p ≤ 0.05. Statistical comparisons were carried out using SPSS.

**Results**

Prior to cord occlusion, all fetuses had fetal arterial blood gas, oxygen saturation and pH parameters that were similar between groups and normal for late gestation fetal sheep [4] (table 1). Compared to that observed in control animals, the 10-min UCO caused significant fetal hypoxemia, hypercapnia and acidosis in both UCO and UCO + melatonin groups (table 1). There were no significant differences in blood gases between the UCO and the UCO + melatonin fetuses.

**Table 1. Fetal arterial blood gas parameters**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>UCO</th>
<th>UCO + melatonin</th>
</tr>
</thead>
<tbody>
<tr>
<td>SaO2, %</td>
<td>Pre-UCO</td>
<td>65.4±3.6</td>
<td>69.4±5.8</td>
</tr>
<tr>
<td></td>
<td>During UCO</td>
<td>68.4±2.2</td>
<td>10.8±1.8*</td>
</tr>
<tr>
<td></td>
<td>Post-UCO</td>
<td>67.5±3.5</td>
<td>71.2±4.8</td>
</tr>
<tr>
<td>P&lt;sub&gt;O2&lt;/sub&gt;, mm Hg</td>
<td>Pre-UCO</td>
<td>22.3±0.5</td>
<td>22.2±1.9</td>
</tr>
<tr>
<td></td>
<td>During UCO</td>
<td>22.4±0.7</td>
<td>8.5±2.7*</td>
</tr>
<tr>
<td></td>
<td>Post-UCO</td>
<td>22.2±0.7</td>
<td>26.6±2.0</td>
</tr>
<tr>
<td>P&lt;sub&gt;CO2&lt;/sub&gt;, mm Hg</td>
<td>Pre-UCO</td>
<td>47.1±1.2</td>
<td>47.9±1.1</td>
</tr>
<tr>
<td></td>
<td>During UCO</td>
<td>44.8±1.7</td>
<td>112.5±3.0*</td>
</tr>
<tr>
<td></td>
<td>Post-UCO</td>
<td>46.3±1.5</td>
<td>46.8±0.4</td>
</tr>
<tr>
<td>pH</td>
<td>Pre-UCO</td>
<td>7.36±0.01</td>
<td>7.36±0.01</td>
</tr>
<tr>
<td></td>
<td>During UCO</td>
<td>7.37±0.01</td>
<td>6.94±0.01*</td>
</tr>
<tr>
<td></td>
<td>Post-UCO</td>
<td>7.36±0.01</td>
<td>7.29±0.02*</td>
</tr>
</tbody>
</table>

Values are mean ± SEM. Three time-points are pre-cord occlusion (pre-UCO) at -1 h relative to occlusion, 10 min into cord occlusion (during UCO) and 1 h after cord occlusion (post-UCO). Significant differences (p < 0.05) are shown as * in control vs. UCO groups, and control vs. UCO + melatonin groups. No differences were detected in UCO vs. UCO + melatonin groups.

Neuroprotective Melatonin in the Fetal Brain
Circadian rhythms for circulating fetal melatonin concentrations were observed in all animals over the pre-treatment period prior to melatonin administration and UCO. There was no difference in daytime (9.8 ± 1.2 pM) or nighttime (45.1 ± 11.2 pM) melatonin concentrations between experimental groups. Maternal administration of melatonin significantly increased fetal arterial plasma melatonin concentration such that after 1 h, fetal levels of melatonin in the UCO + melatonin group were 7,351 ± 1,393 pM compared to 13.4 ± 4.0 pM in the UCO group (p < 0.001). Three hours after cessation of the melatonin infusion (i.e. 4 h after the cord occlusion) fetal melatonin levels were not significantly different between UCO groups; 15.8 ± 3.2 pM in UCO versus 44.8 ± 12.8 pM in UCO + melatonin animals; p > 0.05.

It has been reported previously that UCO for 10 min in late gestation fetal sheep results in cell death, particularly in the hippocampus, basal ganglia/thalamus, and cerebellum [4]. Accordingly, we assessed whether melatonin protected against cell death in these regions of the late gestation fetal brain at 48 h after acute cord occlusion. Pyknotic degenerating neurons were identified using hematoxylin and eosin as shrunken cells with small, densely stained nuclei and eosinophilic cytoplasm. Low numbers of pyknotic cells were observed in the brains of control animals (fig. 1a, g). In UCO animals we observed a 7-fold (p <
Neuroprotective Melatonin in the Fetal Brain

0.0001) increase in pyknotic cells within the CA1 of the hippocampus (fig. 1b, g), compared to controls, and similarly, within the Purkinje layer of the cerebellum UCO fetuses showed a 3-fold (p < 0.05) increase in pyknotic cells versus control fetuses (fig. 1g). Administration of melatonin ameliorated cellular pyknosis in UCO fetuses, such that there was no difference in pyknotic cell numbers in the CA1, thalamus or cerebellum of control and UCO + melatonin fetuses (fig. 1c, f, g). In addition, caspase-3-positive apoptotic cells were observed in the CA1 region of the hippocampus, thalamus and cerebellum of control, UCO and UCO + melatonin fetuses. There was a significant increase in the number of caspase-3-positive cells within the Purkinje layer of the cerebellum in UCO fetuses and this effect was mitigated by melatonin administration (fig. 1h). However there was no significant effect of UCO or melatonin treatment on the number of caspase-3-positive cells within the hippocampus or thalamus.

After UCO, there was a marked increase in the level of staining of GFAP-immunopositive astrocytes within the CA1 region of the fetal hippocampus, the thalamus and the Purkinje layer of the cerebellum, compared with control fetal brains (fig. 3a; p < 0.05). In response to UCO, astrocytes were frequently present and exhibited altered morphology with longer and more numerous processes and larger heavily-stained cell bodies (fig. 2b). These morphological changes were not observed in fetuses in which the ewe had received melatonin (fig. 2c) and UCO + melatonin fetal brains demonstrated decreased GFAP expression compared to UCO alone and were not different to controls (fig. 3a; p < 0.05). As expected, astrocytic processes were found in close association with blood vessels (fig. 2a–c), and these processes also showed increased GFAP immunoreactivity and hypertrophic astrocyte end-feet after UCO (fig. 2b). Plasma albumin was observed in brain parenchyma of UCO fetal brains (fig. 2e), with a significant upregulation of albumin immunoreactivity within hippocampal CA1, thalamus and cerebellar Purkinje cells in UCO versus control brains (fig. 3b; p < 0.05). Albumin immunoreactivity was observed intracellularly in UCO fetal brains, indicative of cellular sequestration of albumin by cells and most notable within the thalamus and cerebellum (images not shown). Albumin staining was rarely seen in UCO + melatonin fetuses in any brain region (fig. 2f), similar to control fetal brains (fig. 2d) and quantification demonstrated that albumin immunoreactivity was not different in UCO + melatonin fetuses and controls (fig. 3b). Within the UCO fetal brains, intense albumin staining was notable in the parenchyma adjacent to blood vessels, indicative of increased blood vessel permeability (fig. 2e) [30]. We quantified the number of albumin-positive vessels and found that UCO induced a significant increase within the thalamus (fig. 3c), compared to control (p < 0.05). The increase in the number of cells and vessels staining positively for albumin following UCO was significantly reduced by prior administration of melatonin to the ewe (fig. 2f, 3b, c).

We assessed the number of Iba-1-positive microglial cells within control, UCO and UCO + melatonin fetal brains. UCO resulted in a significant increase in Iba-1-labeled cells within the cerebellum, compared to control animals (p = 0.05) and this effect was ameliorated in UCO + melatonin animals (fig. 3c). There was no difference in the number of Iba-1-positive microglia across experimental groups within hippocampal CA1 or thalamus (fig. 3c).

Within the hippocampus, thalamus and cerebellum, no 4-HNE-positive cells were observed in control fetuses, indicative of minimal or no brain lipid peroxidation under normal fetal conditions. UCO significantly increased cellular lipid peroxidation in the hippocampus (fig. 2k, 3e; p = 0.005) and thalamus (fig. 3e; p = 0.05; fig. 5h) and the melatonin treatment in UCO + melatonin fetuses completely abolished this lipid peroxidation response (fig. 2l, 3e; p > 0.05 vs. control). Within the hippocampus we used double-label immunohistochemistry to demonstrate that it was predominantly neurons that were susceptible to lipid peroxidation following UCO, with 70–80% of 4-HNE-positive (lipid peroxidation) cells (fig. 2m) also positive for NeuN (neurons). A smaller proportion (<20%) of hippocampal 4-HNE-positive cells were also GFAP-positive astrocytes (fig. 2n), but mature (CNPase-positive) oligodendrocytes were not positive for lipid peroxidation (image not shown).

Discussion

The present study finds that melatonin protects the late gestation fetal brain from the cellular consequences of a severe hypoxic-ischemic insult and the actions of melatonin are likely contributed by several mechanisms. Severe global hypoxia caused by 10 min of UCO produced fetal hypoxia, hypercapnia, and acidosis, which, in turn, induced lipid peroxidation, brain inflammation, increased the penetration of plasma proteins into brain parenchyma, and initiated astrogliosis. The insult induced apoptotic and/or necrotic cell death in the hippocampus and cerebellum, but not in the thalamus. Maternal melatonin administration before and after UCO abolished neuronal lipid peroxidation, prevented cerebrovascular...
Fig. 2. Photomicrographs showing GFAP (a–c), albumin (d–f), Iba-1 (g–i) and 4HNE (j–l) immunoreactivity in the CA1 area of the hippocampus in the fetal brain 48 h after the sham procedure (a–j), UCO (b–k) and UCO + melatonin (c–l). Scale bars = 50 μm. a–c as shown in c, d–f as shown in f, g–i as shown in i, j–l as shown in l. Inset in e shows an albumin-positive blood vessel, scale bar 50 μm. Double-label immunohistochemistry in the hippocampus (m, n) for 4-HNE together with mature neurons (NeuN; m) and mature astrocytes (GFAP; n) in a UCO brain. Cell types (NeuN and GFAP) were visualized with Alexa Fluor 594 (red) and 4-HNE with Alexa Fluor 488 (green). Scale bar = 50 μm as shown in m.
instability, reduced astrogliosis, reduced inflammation and prevented cell death.

UCO increased lipid peroxidation (4-HNE immunostaining) in the fetal brain, supporting and extending our previous observation of UCO-induced stimulation of hydroxyl radical formation within the brain [5]. In the current study, lipid peroxidation was abolished with maternal melatonin treatment. The overproduction of reactive oxygen species, and particularly the highly toxic hydroxyl radical, is potentially very damaging for tissues, an effect exacerbated in the developing brain with its high lipid content and low endogenous levels of antioxidants [17, 18]. Melatonin is a particularly effective scavenger of the hydroxyl radical [31, 32]. Oxidative stress is considered a critical mediator of brain injury and functional deficits [21, 33, 34] and therefore reducing this adverse response following acute hypoxia may protect against cellular damage. This association is supported with our results in the hippocampus, where melatonin ameliorated both cellular lipid peroxidation and pyknosis. However, within the cerebellum we did not find an increase in lipid peroxidation following UCO, but did observe both apoptosis and pyknosis, which were reduced with melatonin administration.

The hippocampus is vulnerable to acute fetal hypoxia in late-term fetal sheep [7, 35] and we also observed a significant increase in the number of pyknotic cells in the CA1 of the hippocampus after UCO. However, at 48 h after the insult, there was no evidence of increased caspase-3-mediated apoptosis within the hippocampus. Although distinguishing between apoptotic and necrotic cellular degeneration was not the main objective of this study, this result probably reflects the continuum from initial necrosis (pyknosis) through to programmed and delayed apoptosis [36]. The pattern and temporal evolution of neuronal death differs between brain regions, which may explain why we showed both increased apoptosis and pyknosis within the cerebellum after UCO, but did not show significant cellular damage within the thalamus. Thalamic neurons are sensitive to hypoxic insults [35, 37], however these cells predominantly respond with programmed apoptotic cell death that is delayed relative to cortical neurons [37] suggesting that the timing of our insult relative to tissue collection may have missed the peak in thalamic neuronal degeneration. Neurons were the principal cell type to stain positively for lipid peroxidation after UCO, reflecting the mature state of the late gestation fetal sheep brain [38], whereas in the preterm brain 48 h after the sham procedure (n = 5), UCO (n = 5) and UCO + melatonin (n = 5). Each bar represents the mean ± SEM; * p < 0.05, control versus UCO.

Fig. 3. Expression of GFAP as a percentage of the field of view (a) and the number of positive albumin cells (b), positive albumin vessels (c), positive Iba-1 (d) and 4-HNE (e) cells in the CA1 area of the hippocampus, the thalamus and the cerebellum, in the fetal brain 48 h after the sham procedure (n = 5), UCO (n = 5) and UCO + melatonin (n = 5). Each bar represents the mean ± SEM; * p < 0.05, control versus UCO.
brain, oligodendrocyte precursor cells are susceptible to oxidative damage contributing to the propensity for preterm white matter damage [39, 40]. Melatonin also provides white matter protection in the preterm brain, protecting oligodendrocyte maturation in growth-restricted rats [41].

The antioxidant actions of melatonin are complemented by its ability to suppress neuro-inflammatory responses by preventing translocation of nuclear factor-κB and reducing subsequent pro-inflammatory cytokine production [20, 29]. Accordingly, we also assessed the distribution and number of Iba-1-positive microglia cells within the brain. We observed an increase in the number of activated microglia in the cerebellum after the hypoxic-ischemic insult, but there was no change within the hippocampus or thalamus. The administration of melatonin in UCO animals ameliorated this cerebellar microglial response. There was no evidence of lipid peroxidation within the cerebellum following UCO, and therefore the finding that melatonin mediated the inflammatory microglial cell response within this region is notable, since both apoptotic and necrotic cell death were reduced with melatonin treatment. This finding supports an anti-inflammatory role for melatonin, however it is also known that oxidative stress and inflammation are intimately linked; reactive oxygen species upregulate inflammatory cytokine production via nuclear factor-κB activation [42] and conversely, activation of brain microglia can induce release of free radicals [43]. The current study cannot separate anti-inflammatory and antioxidant properties of melatonin but, given the strong association between these two systems, it appears that melatonin is a particularly useful neuroprotective agent for the perinatal brain.

Further, we observed that melatonin reduced plasma albumin extravasation in response to acute hypoxia, indicative of cerebrovascular stabilization. The blood-brain barrier (BBB) is relatively impermeable to plasma proteins, such as albumin, in the normal near-term fetal sheep brain, as shown in the current study by the absence of albumin in control brains. Indeed, increased BBB permeability is considered a hallmark of brain injury [44], allowing access of blood-borne products into the extracellular space of the brain. Astrocytes are fundamental in the development and maintenance of the BBB, with endfeet of astrocytes ensheathing brain capillaries [45] and inducing expression of tight-junction proteins [44]. Together with providing cerebrovascular stability, maternal melatonin treatment reduced GFAP-positive astrogliosis in the fetal brain after UCO, restoring the normal, non-hypertrophic morphology of astrocytes. BBB breakdown following hypoxic insults has been the subject of review and is most likely contributed by changes in pro-inflammatory cytokines, nitric oxide and vascular endothelial growth factor [44]. As described above, melatonin has anti-inflammatory actions [29] but it also decreases vascular endothelial growth factor and nitric oxide within the brain [46], suggesting that decreased vascular permeability and astrogliosis with melatonin treatment in the current study are likely to be secondary protective benefits.

The present study shows that treating the mother with melatonin can protect the near-term fetal brain against the effects of global perinatal hypoxia. Brain lipid peroxidation was reduced with melatonin, preferentially protecting the neurons, as they were the principal cellular target for oxidative stress. Melatonin was also anti-inflammatory within the cerebellum, reducing the number of activated microglia cells. Astrogliosis and increased BBB permeability were apparent in hypoxic fetuses, and ameliorated with melatonin. Given the strong safety profile of melatonin, we suggest that melatonin should be considered as an effective therapy for use in complicated pregnancies and at birth to protect the perinatal brain when hypoxia-induced brain damage may occur.

Acknowledgements

The authors wish to acknowledge the technical assistance of Jan Loose and funding provided by the Victorian Government’s Operational Infrastructure Support Program. This project was supported by a grant from the National Health and Medical Research Council of Australia.

References

Neuroprotective Melatonin in the Fetal Brain


Downloaded by: 54.70.40.11 - 11/24/2017 3:42:49 PM